Elizabeth Olson Hexner - Faculty Biosketch

Elizabeth Olson Hexner, M.D., M.S.T.R.

Associate Professor of Medicine at the Hospital of the University of Pennsylvania

Attending Physician, Hospital of the University of Pennsylvania - Rhoads 7 Liquid Tumor Service

Assistant Director, MTR program, Perelman School of Medicine

Medical Director, Center for Cellular Immunotherapies, Perelman School of Medicine

Department: Medicine

Contact information

Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-106
3400 Civic Center Boulevard
Philadelphia, PA 19104

Office: 215-662-6348
Fax: 215-615-5888

Links
Penn Center for Myeloproliferative Neoplasms

Education:
A.B. (French/Comparative Area Studies)
Duke University, 1992.
(Premedical Studies)
Harvard University Extension School, 1994.
M.D. (Medicine)
Columbia College of Physicians and Surgeons, 1999.
M.S.T.R. (Translational Research)
University of Pennsylvania, 2009.

Post-Graduate Training
Intern, Department of Medicine, Columbia Presbyterian Hospital, 1999-2000.
Resident, Department of Medicine, Columbia Presbyterian Hospital, 2000-2002.
Fellow, Hematology/Oncology, University of Pennsylvania, 2002-2005.

Certifications
American Board of Internal Medicine (Internal Medicine), 2002.
American Board of Internal Medicine (Hematology), 2005.
American Board of Internal Medicine (Medical Oncology), 2005.

Permanent link

> Perelman School of Medicine > Faculty > Details

Description of Research Expertise

Myeloproliferative Disorders
Umbilical Cord Blood Transplantation

Selected Publications

Huang, Q., He, S., Tian, Y., Gu, Y., Chen, P., Li, C., Huang, J., Liu, Y., Yu, H., Jin, M., Hu, S., Tong, Q., Ma, A., Jin, J., Hexner, E., Fung, H., Reshef, R., Zhang, Y., Zhang, Y.: Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice. Blood 2017.

Verstovsek, S., Mesa, R. A., Gotlib, J., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M. W., Miller, C. B., Silver, R. T., Talpaz, M., Winton, E. F., Harvey, J. H., Jr., Arcasoy, M. O., Hexner, E. O., Lyons, R. M., Paquette, R., Raza, A., Jones, M., Kornacki, D., Sun, K., Kantarjian, H., Comfort- I. investigators: Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol 10(1): 55, 2017.

Hartwell, M. J., Ozbek, U., Holler, E., Renteria, A. S., Major-Monfried, H., Reddy, P., Aziz, M., Hogan, W. J., Ayuk, F., Efebera, Y. A., Hexner, E. O., Bunworasate, U., Qayed, M., Ordemann, R., Wolfl, M., Mielke, S., Pawarode, A., Chen, Y. B., Devine, S., Harris, A. C., Jagasia, M., Kitko, C. L., Litzow, M. R., Kroger, N., Locatelli, F., Morales, G., Nakamura, R., Reshef, R., Rosler, W., Weber, D., Wudhikarn, K., Yanik, G. A., Levine, J. E., Ferrara, J. L.: An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. JCI Insight 2(3): e89798, 2017.

Gupta, V., Harrison, C., Hexner, E. O., Al-Ali, H. K., Foltz, L., Montgomery, M., Sun, W., Gopalakrishna, P., Kantarjian, H., Verstovsek, S.: The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. Haematologica 101(12): e482-e484, Dec 2016.

Holtan, S. G., Khera, N., Levine, J. E., Chai, X., Storer, B., Liu, H. D., Inamoto, Y., Chen, G. L., Mayer, S., Arora, M., Palmer, J., Flowers, M. E., Cutler, C. S., Lukez, A., Arai, S., Lazaryan, A., Newell, L. F., Krupski, C., Jagasia, M. H., Pusic, I., Wood, W., Renteria, A. S., Yanik, G., Hogan, W. J., Hexner, E., Ayuk, F., Holler, E., Watanaboonyongcharoen, P., Efebera, Y. A., Ferrara, J. L., Panoskaltsis-Mortari, A., Weisdorf, D., Lee, S. J., Pidala, J.: Late acute graft versus host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. Blood Sep 13 2016 Notes: Epub ahead of print.

Yam, C., Crisalli, L., Luger, S. M., Loren, A. W., Hexner, E. O., Frey, N. V., Mangan, J. K., Gao, A., Stadtmauer, E. A., Porter, D. L., Reshef, R.: Unrelated donors are associated with improved relapse free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity allogeneic stem-cell transplantation. Am J Hematol 91(9): 883-7, Sep 2016.

Hexner, E. O., Luger, S. M., Reshef, R., Jeschke, G. R., Mangan, J. K., Frey, N. V., Frank, D. M., Richman, L. P., Vonderheide, R. H., Aqui, N. A., Rosenbach, M., Zhang, Y., Chew, A., Loren, A. W., Stadtmauer, E. A., Levine, B. L., June, C. H., Emerson, S. G., Porter, D. L.: Infusion of CD3/CD28 co-stimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment. Am J Hematol 91(5): 453-60, May 2016.

Ganetsky, A., Shah, A., Miano, T. A., Hwang, W. T., He, J., Loren, A. W., Hexner, E. O., Frey, N. V., Porter, D. L., Reshef, R.: Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation. Bone Marrow Transplant 51(4): 568-72, Apr 2016.

Meng, L., Bai, Z., He, S., Mochizuki, K., Liu, Y., Purushe, J., Sun, H., Wang, J., Yagita, H., Mineishi, S., Fung, H., Yanik, G. A., Caricchio, R., Fan, X., Crisalli, L. M., Hexner, E. O., Reshef, R., Zhang, Y., Zhang, Y.: The Notch Ligand DLL4 Defines a Capability of Human Dendritic Cells in Regulating Th1 and Th17 Differentiation. J Immunol 196(3): 1070-80, Feb 1 2016.

Lewen, M., Gresh, R., Queenan, M., Paessler, M., Pillai, V., Hexner, E., Frank, D., Bagg, A., Aplenc, R., Caywood, E., Wertheim, G.: Pediatric chronic myeloid leukemia with inv(3)(q21q26.2) and T lymphoblastic transformation: a case report. Biomark Res 4: 14, 2016.